- Regeneron Pharmaceuticals has secured past FDA approval for Pasatru (garetosmab-grts), a VelocImmune-derived monoclonal antibody that reduces new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, based on Phase 3 OPTIMA trial data.
- This approval introduces a new rare disease therapy that can be infused monthly, including in home settings, and is supported by strong lesion-reduction outcomes against placebo while carrying specific safety and pregnancy-related precautions.
- We’ll now explore how Pasatru’s entry as a rare disease therapy with home-infusion potential may influence Regeneron’s broader investment narrative.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early
Advertisement
Regeneron Pharmaceuticals Investment Narrative Recap
To own Regeneron, you generally need to believe its high R&D spending will keep turning into new, meaningful therapies as EYLEA faces competition and pricing pressure. Pasatru’s FOP approval reinforces that innovation story, but it is unlikely to change the near term focus on ophthalmology, where EYLEA and EYLEA HD remain the key swing factors and risks to revenue and margins
Among recent developments, the April 2026 FDA decision to extend EYLEA HD dosing intervals up to 20 weeks in wAMD and DME looks especially relevant. That label update aims to make the ophthalmology franchise more resilient against branded and biosimilar anti VEGF rivals, which matters far more to Regeneron’s short term earnings profile than Pasatru’s contribution, even as Pasatru adds a differentiated rare disease therapy to the portfolio
Yet against this progress, investors should also be aware of the growing pressure from lower cost ophthalmology alternatives and how that could eventually affect
Read the full narrative on Regeneron Pharmaceuticals (it’s free!)
Regeneron Pharmaceuticals’ narrative projects $19.4 billion revenue and $6.0 billion earnings by 2029. This requires 9.2% yearly revenue growth and about a $1.6 billion earnings increase from $4.4 billion today
Uncover how Regeneron Pharmaceuticals’ forecasts yield a $833.31 fair value, a 4% upside to its current price
Exploring Other Perspectives
Some of the lowest estimating analysts were already cautious, assuming only about 5.7% annual revenue growth to roughly US$18.3 billion by 2029, and the Pasatru approval could eventually test whether that more pessimistic view on pricing pressure and competition is still reasonable or needs to be revisited
Explore 6 other fair value estimates on Regeneron Pharmaceuticals – why the stock might be worth 9% less than the current price!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own
- A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Regeneron Pharmaceuticals’ overall financial health at a glance.
Curious About Other Options?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
MI
mitchell_lawler
The Foxhole
The world’s in stitches over robots sprinting into walls. I still think they’re the answer to our productivity problem
87
DE
devon_jd15013h
What you have missed is that this event happened last year too. Last year the number was 21 seconds. This year it beat Bolt. That’s 60% improvement in an year. Now extrapolate this in many axes of work that Robots can come and fill in. The physical productivity and AI boom is just starting
LE
LeverageIsLovely14h
I can’t pick a company. But I can pick a person. With no doubt that’s Musk. Optimus for blue collar productivity increase and xAI for white collar productivity increase. Did anyone dabble with GrokBot here?
Andrew Legget
Market Insights
Great earnings season, but are the earnings real?
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
85
Aug 28, 2026
About NasdaqGS:REGN
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide
See The Free Research Report
Flawless balance sheet and good value
See The Free Research Report
Similar Companies
AbbVie
NasdaqGS:AMGN
Amgen
Market Insights
Great earnings season, but are the earnings real?AN
Andrew Legget
Which payment stocks actually get paid?MI
Mitchell Lawler
Picking portfolio winners takes more than hot airAN
Andrew Legget
Advertisement
Weekly Picks
LO
Lou_Baseneseon Oncolytics Biotech·13 days ago
The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech
Fair Value:US$3.576.1% undervalued
43followersusers have followed this narrative
·0commentsusers have commented on this narrative
·12likesusers have liked this narrative
TR
tripledubon Meta Platforms·28 days ago
The $135 Billion Bet That Should Make Every Shareholder Nervous
Fair Value:US$5862.4% undervalued
63followersusers have followed this narrative
·3commentsusers have commented on this narrative
·34likesusers have liked this narrative
TA
Taloson Voyager Technologies·22 days ago
The “Landlord of Orbit” – A Deep Value Play Ahead of the Starlab Era
Fair Value:US$385.291.3% undervalued
68followersusers have followed this narrative
·0commentsusers have commented on this narrative
·6likesusers have liked this narrative
IV
Ivoedon Uber Technologies·16 days ago
Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides
Fair Value:US$11634.8% undervalued
14followersusers have followed this narrative
·0commentsusers have commented on this narrative
·3likesusers have liked this narrative
RecentlyUpdated Narratives
LU
LunaRodason Science Applications International·about 7 hours ago
SAIC | Science Applications International: What They Said vs. What They Did
Fair Value:US$119.247.5% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
AN
Anthony_Leeon Lotus Technology·about 10 hours ago
Tech and Tradition: Lotus Technology’s Compound Formula in Luxury EVs
Fair Value:US$2.5354.2% undervalued
2followersusers have followed this narrative
·5commentsusers have commented on this narrative
·1likeusers have liked this narrative
EP
Epstein_Researchon Dryden Gold·about 11 hours ago
Dryden Gold continues to expand & de-risk its flagship Gold Rock project!
Fair Value:CA$173.0% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28021.3% undervalued
369followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 2 months ago
A wonderful business at reasonable price
Fair Value:US$419.9120.8% overvalued
214followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
JO
John_Ericon MercadoLibre·26 days ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$7.31k73.5% undervalued
125followersusers have followed this narrative
·3commentsusers have commented on this narrative
·18likesusers have liked this narrative
